Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06163664
Other study ID # UP-23-00541
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date December 15, 2024
Est. completion date November 30, 2025

Study information

Verified date June 2024
Source University of Southern California
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Previous studies have demonstrated that patients frequently undergo significant decision conflict regarding major medical decisions in otolaryngology. There lack validated tools available for decision support for patients. While limited evidence has demonstrated that clinical decision support tools can alleviate decision conflict for patients with diagnosis in otolaryngology, conversational language models were not employed in these studies and may provide additional benefit in this context. This study seeks to evaluate the efficacy of using ChatGPT, a conversational language model with basic clinical knowledge, in alleviating decision conflict for patients with new diagnosis in otolaryngology. For this pilot study, vestibular schwannoma, a benign tumor that develops on the vestibular nerve with known clinical equipoise, has been chosen for the initial study diagnosis. Efficacy will be evaluated by comparison of responses to the Decisional Conflict Scale (DCS) and Satisfaction with Decision (SWD) scores between a group given training in ChatGPT and a control group (no ChatGPT training).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date November 30, 2025
Est. primary completion date June 30, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years or older - Diagnosed with vestibular schwannoma - Have access to internet-enabled device that is compatible with ChatGPT Exclusion Criteria: - < 18 years old - patient without diagnosis of vestibular schwannoma - patient does not have access to internet-enabled device - patient who declines study participation

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Use of chatGPT for 1 week
Use of chatGPT for 1 week

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University of Southern California

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in scores of Decisional Conflict Scale after ChatGPT use The Decisional Conflict Scale (DCS) measures 5 dimensions of decision making (feeling: uncertain, uninformed, unclear about values, unsupported; ineffective decision making). 15-item validated questionnaire. Score range 5-75 (higher score corresponding to higher levels of conflict in decision making) baseline, 1 week follow up, 2 week follow up
Primary Changes in scores of Satisfaction with Decision after ChatGPT use The Satisfaction with Decision (SWD) scale measures satisfaction with health care decisions. 6-item validated questionnaire. Score range 5-30 (higher score corresponding to higher levels of satisfaction with decision) baseline, 1 week follow up, 2 week follow up
Primary Changes in scores for Knowledge on vestibular schwannoma management after ChatGPT use 4-item questionnaire (Likert scale) assessing participants' confidence in understanding the diagnosis and treatment options for vestibular schwannoma. Score range 5-20 (higher score corresponding to higher levels of confidence in understanding diagnosis and management of vestibular schwannoma) baseline, 1 week follow up, 2 week follow up
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04196933 - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma N/A
Active, not recruiting NCT00973739 - Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Phase 2
Completed NCT04351373 - Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560 Phase 2
Active, not recruiting NCT01449604 - Stereotactic Radiation in Vestibular Schwannoma Phase 3
Completed NCT01207687 - Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Phase 2
Not yet recruiting NCT05567341 - Remote Ischemic Preconditioning in Vestibular Schwannoma Surgery N/A
Completed NCT02249572 - Vestibular Schwannoma - Radiosurgery or Expectation: V-REX. N/A
Terminated NCT05116878 - Enhancing Facial Nerve Function With Omega-3 After Resection of Vestibular Schwannoma N/A
Suspended NCT03095248 - Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Phase 2
Recruiting NCT04801953 - Nimodipine in Vestibular Schwanommas Phase 2
Recruiting NCT03745560 - Intraoperative EABR for Decision Making
Recruiting NCT04859335 - Evolution of Balance and Vestibular Function in Patients Treated With Gammaknife Radiosurgery for Vestibular Schwannoma N/A
Recruiting NCT04128345 - Novel Multimodality Imaging for Navigation in Skull Base Surgery
Active, not recruiting NCT01199978 - Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma Phase 2
Recruiting NCT04057976 - Use of DTT to Define Facial Nerve Position in Vestibular Schwannomas N/A
Completed NCT00863122 - Concentration and Activity of Lapatinib in Vestibular Schwannomas Early Phase 1
Recruiting NCT04374305 - Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) Phase 2
Recruiting NCT03079999 - Study of Aspirin in Patients With Vestibular Schwannoma Phase 2
Recruiting NCT05786144 - Vestibular Schwannoma Organoids
Recruiting NCT03593577 - Secondary Endolymphatic Hydrops and Vestibular Schwannomas on 3 Tesla MRI